BFM
COGT icon

Boothbay Fund Management’s Cogent Biosciences COGT Stock Holding History

Boothbay Fund Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-96,400
Closed -$692K – 1900
2025
Q2 		$692K Buy
+96,400
New +$534K 0.01% 802

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Boothbay Fund Management's COGT Position: Q1 2026 in Review

Boothbay Fund Management reduced its Cogent Biosciences (COGT) stake by 3.8% in Q1 2026, selling an estimated $179K and leaving 122,228 shares worth $4.7M. The position accounts for 0.06% of the portfolio, ranked #337.

Boothbay Fund Management first reported a position in COGT in Q1 2021 and has held it in 7 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Boothbay Fund Management held 122,228 shares of Cogent Biosciences worth $4.7M as of Q1 2026.
  • Boothbay Fund Management sold 4,847 Cogent Biosciences shares in Q1 2026, an estimated $179K.
  • Cogent Biosciences made up 0.06% of Boothbay Fund Management's portfolio in Q1 2026, its #337 holding.
  • Boothbay Fund Management first reported a position in Cogent Biosciences in Q1 2021 and has held it in 7 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.